Q32 Bio shares up 26% on $55 million financing round

Investing.com -- Q32 Bio (NASDAQ: QTTB) shares climbed 26% to $8.94 in premarket trading on Wednesday following the announcement of a $55 million private placement financing.

The company, which develops therapies for alopecia areata and other autoimmune and inflammatory diseases, sold approximately 6.9 million shares and pre-funded warrants at $8 per share.

BVF Partners led the private placement, with participation from RA Capital Management, OrbiMed, and Atlas Venture. Morgan Stanley served as lead placement agent alongside Oppenheimer.

Q32 Bio shares closed up 22% at $7.09 on Tuesday, bringing year-to-date gains to approximately 114%.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Future Money Acquisition gets Nasdaq notice over late 10-Q filing
• Krait Critical Minerals closes $1.22M first tranche of placement